Skip to main content
. 2020 Nov 3;51(2):273–283. doi: 10.1111/cea.13765

Table 3.

Proportion of patients with CompEx events

AZD9412 (N = 61) Placebo (N = 60) Ratio of proportions (95% CI) AZD9412 vs Placebo p‐value
n (%) n (%)

Treatment

Days 1 to 15

17 (27.9%) 18 (30.0) 0.85 (0.48, 1.52) .59

Post‐treatment

Days 15 to 30

9 (14.8) 12 (20.0) 0.74 (0.34, 1.61) .45

CompEx: composite endpoint for severe exacerbations; n: number; and vs: versus.